Session 26 - 12th CROI

Home

Session 26 Poster Discussion
Poster Discussion: Therapeutic Drug Monitoring
Thursday, 2:30 - 3:30 pm
312

639	Prospective Trial to Evaluate how Therapeutic Drug Monitoring of Protease Inhibitors Increases Virologic Success and Tolerance of HAART (COPHAR 2 - ANRS 111 trial) F Mentré², Xavier Duval*¹, E Rey³, G Peytavin⁴, S Auleley², M Legrand², M Biour⁵, A Bouxin⁶, C Goujard⁷, A M Taburet⁷, C Katlama⁸, B Diquet⁸, C Lascoux⁹, J M Tréluyer³, and D Salmon-Céron¹⁰ ¹Hosp Bichat-Claude Bernard, Paris, France; ²INSERM EMI 0357, Hosp Bichat-Claude Bernard, Paris, France; ³Hosp St-Vincent de Paul, Paris, France; ⁴Hosp Bichat-Claude Bernard, Paris, France; ⁵Hosp St-Antoine, Paris, France; ⁶French Agency for AIDS Res, Paris, France; ⁷Hosp Bicêtre, Paris, France; ⁸Hosp Pitie-Salpetriere, Paris, France; ⁹Hosp St-Louis, Paris, France; and ¹⁰Hosp Cochin, Paris, France
640	Determinants of the Need for Therapeutic Drug Monitoring: Rates and Predictors from CCTG 578 Richard Haubrich*¹, B Best¹, M Witt², M Goicoechea¹, C Kemper³, R Larsen⁴, C Diamond⁵, J Tilles⁵, P Heseltine⁶, E Capparelli¹, G Wagner⁷, E Seefried¹, A Rigby¹, J McCutchan¹, and California Collaborative Treatment Group ¹Univ of California, San Diego, USA; ²Harbor-UCLA Med Ctr, Univ of California, Los Angeles, Torrance, USA; ³Santa Clara Valley Med Ctr, San Jose, CA, USA; ⁴Univ of Southern California, Los Angeles, USA; ⁵Univ of California, Irvine, USA; ⁶Quest Diagnostics, San Juan Capistrano, CA, USA; and ⁷Rand Corp, Santa Monica, CA, USA
641	A Computer Artificial Intelligence System to Aid in the Interpretation of Plasma Lopinavir and Efavirenz Drug Concentrations M Goicoechea¹, A Vidal¹, E Capparelli¹, A Rigby¹, C Kemper², R Larsen³, C Diamond⁴, W Mallory⁵, Richard Haubrich*¹, and California Collaborative Treatment Group ¹Univ of California, San Diego, USA; ²Santa Clara Valley Med Ctr, San Jose, CA, USA; ³Univ of Southern California, Los Angeles, USA; ⁴Univ of California, Irvine, USA; and ⁵Harbor-UCLA Med Ctr, Univ of California, Los Angeles, Torrance, USA
642	Frequent Sampling in Virologically Suppressed Patients Taking HIV Protease Inhibitors or Non-nucleoside Reverse Transcriptase Inhibitors Defines Intra-individual Pharmacokinetic Variability Richard Nettles*¹, T Kieffer¹, T Parsons¹, J Johnson¹, T Quinn², B Jackson¹, J Cofrancesco¹, J Gallant¹, K Carson³, R Siliciano^1,4, and C Flexner¹ ¹Johns Hopkins Univ Sch of Med, Baltimore, MD, USA; ²National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD, USA; ³Johns Hopkins Univ, Bloomberg Sch of Publ Hlth, Baltimore, MD, USA; and ⁴Howard Hughes Med Inst, Baltimore, MD, USA
643	Pharmacokinetic and Pharmacodynamic Determinants of Virological Response to Enfuvirtide-based Regimens Stefano Bonora*¹, D Gonzalez de Requena¹, A Castagna², D Aguilar Marucco¹, H Hasson², L Veronese¹, M Sciandra¹, A D'Avolio¹, A Ibanez¹, A Sinicco¹, A Lazzarin², and G Di Perri¹ ¹Univ of Torino, Italy and ²Vita-Salute San Raffaele Univ, Milan, Italy
644	Durability of Viral Suppression according to Self-reported Non-adherence and Antiretroviral Plasma Levels Maria Paola Trotta*¹, S Bonora², A Cozzi-Lepri³, A Ammassari⁴, P Marconi¹, N Ladisa⁵, P Nasta⁶, L Sighinolfi⁷, M Zaccarelli¹, A Riva⁸, G Madeddu⁹, P De Longis¹, A d'Arminio Monforte¹⁰, G Di Perri², A Antinori¹, and AdICoNA Study Group ¹INMI, IRCCS L Spallanzani, Rome, Italy; ²Univ degli Studi, Torino, Italy; ³Royal Free and Univ Coll Med Sch, London, UK; ⁴Univ Cattolica S Cuore, Rome, Italy; ⁵Policlin Univ, Bari, Italy; ⁶Univ degli Studi, Brescia, Italy; ⁷Hosp S Anna, Ferrara, Italy; ⁸Univ degli Studi, Ancona, Italy; ⁹Univ degli Studi, Sassari, Italy; and ¹⁰Hosp Luigi Sacco, Univ degli Studi, Milan, Italy
645	Atazanavir Ctrough Is Associated with Efficacy and Safety: Definition of Therapeutic Range Daniel Gonzalez de Requena*¹, S Bonora¹, F Canta¹, R Marrone¹, A D’Avolio¹, M Sciandra¹, M Milia², A Di Garbo², A Sinicco¹, and G Di Perri¹ ¹Univ of Torino, Italy and ²Amedeo di Savoia Hosp, Torino, Italy